Conference Presentations

PLENARY SESSIONS

  • THIRD PLENARY SESSION: EXAMINING THE ROLE OF PATIENT PREFERENCES TO INFORM REGULATORY DECISIONS

    Presentation

    Shelby D. Reed
    PhD, RPh, Professor, Duke University, Durham, USA
    Matt Reaney
    FRSPH, MSc, Global Head of Clinical Outcomes, Sanofi, Guildford, UK
    Jeff Shuren
    MD, JD, Director, Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA), Silver Spring, USA
    Bennett Levitan
    MD, PhD, Senior Director, Benefit-risk Assessment, Janssen Research & Development, LLC, Epidemiology, Titusville, USA

ISSUE PANEL PRESENTATIONS

  • IP10 : PRIOR AUTHORIZATION POLICIES FOR MANAGING SPECIALTY DRUG SPENDING IN THE UNITED STATES: CAN WE STRIKE A BALANCE BETWEEN APPROPRIATE UTILIZATION AND APPROPRIATE ACCESS?

    Presentation

    Cat Davis Ahmed
    MBA, Vice President, Policy and Outreach, The FH Foundation, Pasadena, USA
  • IP10 : PRIOR AUTHORIZATION POLICIES FOR MANAGING SPECIALTY DRUG SPENDING IN THE UNITED STATES: CAN WE STRIKE A BALANCE BETWEEN APPROPRIATE UTILIZATION AND APPROPRIATE ACCESS?

    Presentation

    Seth J. Baum
    MD, President, American Society for Preventive Cardiology; Chief Medical Officer, Excel Medical Clinical Trials, Affiliate Professor of Medicine, Schmidt College of Medicine, Florida Atlantic University (FAU), Boca Raton, USA
  • IP11 : “MAKING MEDICINES AFFORDABLE: A NATIONAL IMPERATIVE” – REFLECTIONS ON THE NATIONAL ACADEMIES REPORT (Invited Issue Panel)

    Presentation

  • IP11 : “MAKING MEDICINES AFFORDABLE: A NATIONAL IMPERATIVE” – REFLECTIONS ON THE NATIONAL ACADEMIES REPORT (Invited Issue Panel)

    Presentation

    Stacie B. Dusetzina
    PhD, Associate Professor, Health Policy, Vanderbilt University School of Medicine, Ingram Associate Professor of Cancer Research, Nashville, USA
  • IP13 : SURROGATE OUTCOMES IN ONCOLOGY: HOW CAN THEY BE USED TO PREDICT OVERALL SURVIVAL IN CLINICAL PRACTICE AND PAYER DECISION MAKING?

    Presentation

    Louis P. Garrison
    PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, School of Pharmacy, Seattle, USA
  • IP16 : IN THE ELECTRONIC HEALTH RECORD ERA, DO WE STILL NEED CLINICAL REGISTRIES?

    Presentation

    Lisa M. Wruck
    PhD, Director, Duke Clinical Research Institute, Center for Predictive Medicine, Durham, USA
    Marc Berger
    MD, Vice President, Pfizer, Inc., Real World Data and Analytic, New York, USA
    Sharon Hensley Alford
    PhD, Associate Chief Health Officer, IBM Watson Health, Cambridge, USA
    Matthew T. Roe
    MD, MHS, Professor of Medicine, Duke University, Duke Clinical Research Institute, Durham, USA
  • IP17 : HAS THE TIME COME TO REPLACE RANDOMIZED CONTROLLED TRIALS WITH REAL-WORLD DATA -- A CASE OF MEDICAL DEVICES?

    Presentation

    Katarzyna Kolasa
    PhD, Senior Research Fellow, Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
  • IP17 : HAS THE TIME COME TO REPLACE RANDOMIZED CONTROLLED TRIALS WITH REAL-WORLD DATA -- A CASE OF MEDICAL DEVICES?

    Presentation

    Cynthia Iglesias
    PhD, Senior Research Fellow, University of York, Centre for Health Economics, York, UK
  • IP19 : VALUE ASSESSMENT FRAMEWORKS IN AN ERA OF PERSONALIZED MEDICINE: SHARED OBJECTIVES OR IRRECONCILABLE DIFFERENCES?

    Presentation

    Robert W Dubois
    MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, USA
    Kristen Migliaccio-Walle
    BS, Director, Xcenda, LLC, Global Health Economics & Outcomes Research, Palm Harbor, USA
    Daniel A Ollendorf
    PhD, Chief Scientific Officer, Institute for Clinical and Economic Review, Boston, USA
    Sara Traigle van Geertruyden
    JD, Executive Director, Partnership to Improve Patient Care, Washington, USA
  • IP20 : THE PATIENT PERSPECTIVE AND VALUE ASSESSMENT: EASY TO IDENTIFY THE NEED, HARD TO AGREE ON THE SOLUTION

    Presentation

    Josh Seidman
    PhD, MHS, Senior Vice President, Avalere, Washington, USA
  • IP20 : THE PATIENT PERSPECTIVE AND VALUE ASSESSMENT: EASY TO IDENTIFY THE NEED, HARD TO AGREE ON THE SOLUTION

    Presentation

    Ilene L. Hollin
    PhD, MPH, Health Policy Fellow, National Pharmaceutical Council and University of Southern California Schaeffer Center for Health Policy and Economics, Washington, USA
  • IP20 : THE PATIENT PERSPECTIVE AND VALUE ASSESSMENT: EASY TO IDENTIFY THE NEED, HARD TO AGREE ON THE SOLUTION

    Presentation

    Mike Ciarametaro
    MBA, Director of Research, National Pharmaceutical Council, Washington, USA
  • IP22 : CHALLENGES AND OPPORTUNITIES IN THE USE OF REAL-WORLD EVIDENCE FOR REGULATORY DECISION MAKING FOR IN VITRO DIAGNOSTICS

    Presentation

    Tyler J. O'Neill
    DVM, MSc, PhD, Scientist, Roche Diagnostics, Diagnostics Information Solutions, Pleasanton, USA
    Asif Jan
    PhD, Lead, Roche Diagnostics, Diagnostics Information Solutions, Pleasanton, USA
    Brad Spring
    BS, Vice President, BD Life Sciences, Regulatory Affairs, Sparks, USA
    Michael S. Waters
    PhD, SHIELD Team Lead; CDRH RWE Tactical Team – Diagnostics, Food and Drug Administration (FDA), Office of in vitro Diagnostics and Radiologic Health (OIR), Silver Spring, USA
  • IP23 : ESTIMATING SAMPLE SIZE FOR QUALITATIVE RESEARCH IN CLINICAL OUTCOME ASSESSMENT RESEARCH: ONE SIZE DOES NOT FIT ALL!

    Presentation

    Helen Doll
    PhD, Strategic Lead, Quantitative Science, Clinical Outcomes Solutions, Folkestone, UK
  • IP23 : ESTIMATING SAMPLE SIZE FOR QUALITATIVE RESEARCH IN CLINICAL OUTCOME ASSESSMENT RESEARCH: ONE SIZE DOES NOT FIT ALL!

    Presentation

    Katy Benjamin
    PhD, MS, Director, Patient Reported Outcomes, ICON, Bethesda, USA
  • IP23 : ESTIMATING SAMPLE SIZE FOR QUALITATIVE RESEARCH IN CLINICAL OUTCOME ASSESSMENT RESEARCH: ONE SIZE DOES NOT FIT ALL!

    Presentation

    Helen Kitchen
    MSc, Senior Consultant, DRG Abacus, Clinical Outcomes Assessment, Manchester, UK
  • IP23 : ESTIMATING SAMPLE SIZE FOR QUALITATIVE RESEARCH IN CLINICAL OUTCOME ASSESSMENT RESEARCH: ONE SIZE DOES NOT FIT ALL!

    Presentation

    Kathryn Lasch
    PhD, Executive Director, Patient Reported Outcomes, Pharmerit International, Newton, USA
  • IP9 : LIES, DAMNED LIES AND COST-EFFECTIVENESS: OPEN-SOURCE MODELS ARE ESSENTIAL IF COST-EFFECTIVENESS ANALYSES ARE TO BE WIDELY ACCEPTED

    Presentation

    Renée J G Arnold
    PharmD, Director, Navigant Consulting, Inc., Life Sciences, San Francisco, USA
  • IP9 : LIES, DAMNED LIES AND COST-EFFECTIVENESS: OPEN-SOURCE MODELS ARE ESSENTIAL IF COST-EFFECTIVENESS ANALYSES ARE TO BE WIDELY ACCEPTED

    Presentation

    J. Jaime Caro
    MDCM, FRCPC, FACP, Chief Scientist, Evidera, Lexington, USA
  • IP9 : LIES, DAMNED LIES AND COST-EFFECTIVENESS: OPEN-SOURCE MODELS ARE ESSENTIAL IF COST-EFFECTIVENESS ANALYSES ARE TO BE WIDELY ACCEPTED

    Presentation

    Neil Hawkins
    PhD, Professor of Health Technology Assessment (HTA), University of Glasgow, Health Economics & Health Technology Assessment, Glasgow, UK

WORKSHOP PRESENTATIONS

  • W1 : TIME TO LOOK BEYOND KAPLAN-MEIER CURVES? CHALLENGES AND OPPORTUNITIES IN OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TRIALS -- SCIENTIFIC RATIONALE FOR USING PATIENT-LEVEL BIOMEDICAL INFORMATION (Advanced Workshop)

    Presentation

    Yiduo Zhang
    PhD, Director, Health Economics and Payer Analytics, AstraZeneca, Global Payer Evidence and Pricing, Gaithersburg, USA
  • W1 : TIME TO LOOK BEYOND KAPLAN-MEIER CURVES? CHALLENGES AND OPPORTUNITIES IN OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TRIALS -- SCIENTIFIC RATIONALE FOR USING PATIENT-LEVEL BIOMEDICAL INFORMATION (Advanced Workshop)

    Presentation

    Pralay Mukhopadhyay
    PhD, Statistician, Astrazeneca, Gaithersburg, USA
  • W1 : TIME TO LOOK BEYOND KAPLAN-MEIER CURVES? CHALLENGES AND OPPORTUNITIES IN OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TRIALS -- SCIENTIFIC RATIONALE FOR USING PATIENT-LEVEL BIOMEDICAL INFORMATION (Advanced Workshop)

    Presentation

    Scott D. Ramsey
    MD, PhD, Director, Fred Hutchinson Cancer Research Center and University of Washington, Public Health Sciences, Seattle, USA
  • W10 : MILLION DOLLAR THERAPIES FOR RARE CONDITIONS: RETHINKING VALUE

    Presentation

  • W10 : MILLION DOLLAR THERAPIES FOR RARE CONDITIONS: RETHINKING VALUE

    Presentation

    Paul Melmeyer
    MPP, Director of Federal Policy, National Organization for Rare Disorders (NORD), Washington, USA
  • W11 : CHOOSING THE APPROPRIATE MODELING METHOD: CAUSAL MODELING, HEALTH ECONOMIC MODELING, CONSTRAINED OPTIMIZATION OR SIMULATION?

    Presentation

    Kalyan S. Pasupathy
    PhD, Faculty, Mayo Clinic, Healthcare Policy & Research, Rochester, USA
    Deborah A Marshall
    PhD, Professor, University of Calgary, Calgary, Canada
    Praveen Thokala
    PhD, Research Fellow, University of Sheffield, School of Health and Related Research, Sheffield, UK
    William H Crown
    PhD, Chief Scientific Officer, OptumLabs, Cambridge, USA
  • W12 : COMPLEX REAL-WORLD EVIDENCE: NETWORKED AND MISSING DATA (Advanced Workshop)

    Presentation

    Alisa Stephens-Shields
    PhD, Assistant Professor, University of Pennsylvania, Perelman School of Medicine, Department of Biostatistics, Epidemiology and Informatics, Philadelphia, USA
  • W12 : COMPLEX REAL-WORLD EVIDENCE: NETWORKED AND MISSING DATA (Advanced Workshop)

    Presentation

    Laura Hatfield
    PhD, Associate Professor, Harvard Medical School, Department of Health Care Policy, Boston, USA
  • W2 : WHAT IS PATIENT EXPERIENCE DATA? THE REGULATORY PERSPECTIVE

    Presentation

    Megan Moncur
    M.S, Scientist, U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, USA
    Martin Ho
    U.S. Food and Drug Administration, Center for Devices and Radiological Health,
    Pujita Vaidya
    MPH, Director (Acting), Decision Support and Analysis Team, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Office of Strategic Programs/Office of Program and Strategic Analysis, Silver Spring, USA
    Elektra Papadopoulos
    MD, MPH, Associate Director, Clinical Outcome Assessments Staff, U.S. Food and Drug Administration, Office of New Drugs, Center for Drug Evaluation and Research (CDER), Silver Spring, USA
  • W3 : DIGITAL HEALTH: EVALUATING THE EVIDENCE, IDENTIFYING GAPS, PRODUCING BETTER SCIENCE

    Presentation

    Murray Aitken
    MBA, Executive Director, IQVIA Institute for Human Data Science, New York, USA
    Karen Schoelles
    MD, SM, Project Director, AHRQ Healthcare Horizon Scanning System and Director, ECRI Institute Evidence-based Practice Center, ECRI Institute, Technology Assessment, Plymouth Meeting, USA
    Penny Mohr
    MA, Senior Program Officer, Patient-Centered Outcomes Research Institute (PCORI), Improving Healthcare Systems, Washington, USA
    Jasmine Bihm
    DrPH, MPH, Staff Fellow, Agency for Healthcare Research and Quality (AHRQ), Center for Evidence and Practice Improvement, Rockville, USA
  • W3 : DIGITAL HEALTH: EVALUATING THE EVIDENCE, IDENTIFYING GAPS, PRODUCING BETTER SCIENCE

    Presentation

    Murray Aitken
    MBA, Executive Director, IQVIA Institute for Human Data Science, New York, USA
    Jasmine Bihm
    DrPH, MPH, Staff Fellow, Agency for Healthcare Research and Quality (AHRQ), Center for Evidence and Practice Improvement, Rockville, USA
  • W4 : BIOSIMILARS, UTILIZATION, AND POST-MARKETING SURVEILLANCE IN THE UNITED STATES (Invited Workshop)

    Presentation

    Cate Lockhart
    PharmD, PhD, Program Director, Biologics and Biosimilars Collective Intelligence Consortium, Alexandria, USA
    Mark J. Cziraky
    PharmD, CLS, Vice President of Research, Healthcore, Wilmington, USA
    Mike Blum
    MD, MPH, Deputy Director, U.S. Food & Drug Administration, Office of Pharmacovigilance and Epidemiology, Silver Spring, USA
  • W6 : ECONOMIC EVALUATION OF VACCINATION PROGRAMS: EXPLORING MULTIPLE METHODS

    Presentation

    Americo Cicchetti
    DSc, Professor of Management and Healthcare Management & Director, Catholic University of Sacred Heart (ALTEMS), Graduate School of Health Economics and Management, Rome, Italy
  • W6 : ECONOMIC EVALUATION OF VACCINATION PROGRAMS: EXPLORING MULTIPLE METHODS

    Presentation

    David E Bloom
    PhD, Clarence James Gamble Professor of Economics and Demography, Harvard University, TH Chan School of Public Health, Boston, USA
    Josephine Mauskopf
    PhD, Vice President, RTI Health Solutions, Health Economics, Research Triangle Park, USA
  • W7 : ARTIFICIAL INTELLIGENCE AND PRECISION MEDICINE: DOES THE HEALTH ECONOMIST NEED TO ADAPT TO THE MACHINE?

    Presentation

    Augustin Terlinden
    Msc, Health Economist, Navigha, Health Economics, Tervuren, Belgium
    Amine Aissaoui
    PhD in Economics, PharmD, MSc, Researcher, Paris Dauphine University, PSL, LEDA-LEGOS, Paris, France
    Olivier Ethgen
    MSc, PhD, Adjunct Professor Health Economics, University of Liege, Liege, Belgium
    Patricia A Deverka
    MD, MS, MBE, Senior Researcher, American Institutes for Research, Chapel Hill, USA
  • W8 : ASSESSING PATIENT FUNCTIONING IN DRUG DEVELOPMENT USING PERFORMANCE OUTCOME ASSESSMENTS: EVIDENTIARY, METHODOLOGICAL, AND OPERATIONAL CONSIDERATIONS

    Presentation

    Elektra Papadopoulos
    MD, MPH, Associate Director, Clinical Outcome Assessments Staff, U.S. Food and Drug Administration, Office of New Drugs, Center for Drug Evaluation and Research (CDER), Silver Spring, USA
  • W8 : ASSESSING PATIENT FUNCTIONING IN DRUG DEVELOPMENT USING PERFORMANCE OUTCOME ASSESSMENTS: EVIDENTIARY, METHODOLOGICAL, AND OPERATIONAL CONSIDERATIONS

    Presentation

    Heather Adams
    PhD, Associate Professor, University of Rochester Medical Center, Department of Neurology & Pediatrics, Rochester, USA
  • W9 : NUMBERS OR NOISE? INTERPRETING INTERNAL VALIDITY TESTS OF STATED-PREFERENCE DATA (Advanced Workshop)

    Presentation

    Kathryn O’Callaghan
    PhD, Assistant Director of Strategic Programs, U.S. Food and Drug Administration, Center for Devices and Radiological Health, Silver Spring, USA
  • W9 : NUMBERS OR NOISE? INTERPRETING INTERNAL VALIDITY TESTS OF STATED-PREFERENCE DATA (Advanced Workshop)

    Presentation

    Kevin Marsh
    PhD, Director, Evidera, Modelling and Simulation and Senior Research Scientist, Health Economics, London, UK
  • W9 : NUMBERS OR NOISE? INTERPRETING INTERNAL VALIDITY TESTS OF STATED-PREFERENCE DATA (Advanced Workshop)

    Presentation

    Jui-Chen Yang
    MEM, Research Economist, Duke Clinical Research Institute, Preference Evaluation Research Group, Durham, USA

ISPOR FORUMS

  • F1 : HEALTH STATE UTILITY (HSU) GOOD PRACTICES TASK FORCE RECOMMENDATIONS FOR IDENTIFICATION AND USE OF HSU DATA IN COST-EFFECTIVENESS IN DECISION MODELLING

    Presentation

    A. Simon Pickard
    PhD, Professor, University of Illinois at Chicago, College of Pharmacy, Chicago, USA
    Bruce Crawford
    MA, MPH, Senior Principal, IMS Japan K.K., Real-World Evidence Solutions, Japan & APAC, Minato-ku, Tokyo, Japan
    John E. Brazier
    PhD, Professor, University of Sheffield, Health Economics, School of Health and Related Research, Sheffield, UK
  • F2 : HANDLING MISSING VALUES IN REAL-WORLD DATA: ARE THERE CHALLENGES FOR REGULATORY DECISIONS FOR MEDICAL PRODUCTS?

    Presentation

    Judith J. Stephenson
    SB, SM, Principal Scientist, Survey Research, HealthCore, Inc., Wilmington, USA
    Nneka C. Onwudiwe
    PhD, PharmD, MBA, PRO/PE Regulatory Reviewer, U.S. Food and Drug Administration, Office of Prescription Drug Promotion, CDER, Silver Spring, USA
    Samuel Wilson
    PhD, BS, MS, Associate Director-Statistics, Astellas Pharmaceuticals US, Inc., Northbrook, USA
    Helene Karcher
    X-Eng, MIT PhD, Managing Vice-President, Global Head, Real World Modeling, LASER Analytica, London, UK
    Laurence Djatche
    PharmD, Health Economics and Outcomes Research Post-Doctoral Fellow, Thomas Jefferson University, College of Population Health, Philadelphia, USA
  • F3 : DEFINING PATIENT CENTEREDNESS AND ENGAGEMENT IN HEOR: PROPOSED DEFINITION AND STAKEHOLDER RESPONSE

    Presentation

    Rachel L. Harrington
    BA, Pre-Doctoral Fellow, University of Illinois at Chicago, Institute for Health Research and Policy/College of Pharmacy, Chicago, USA
    Suzanne Schrandt
    JD, Director, Patient Engagement, Arthritis Foundation, Atlanta, USA
    Eleanor M. Perfetto
    PhD, MS, Professor, Pharmaceutical Health Services Research, University of Maryland, National Health Council, and Senior Vice President, Strategic Initiatives, Washington, USA
    Sarah Donelson
    MA, Lead, Patient-Centered Research, Genentech, San Francisco, USA
  • F4 : THE ISPOR HEOR COMPETENCIES FRAMEWORK™: GUIDING PROFESSIONAL DEVELOPMENT FOR THE FIELD OF HEOR

    Presentation

    Laura T. Pizzi
    PharmD, MPH, Professor and Director, Rutgers University, Center for Health Outcomes Policy and Economics, Piscataway, USA
    Bill Marder
    PhD, MA, BA, Chief Data Strategist, IBM Watson Health, Cambridge, USA
  • F5 : ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK

    Presentation

    Sang-Soo Lee
    MBA, Director, Corporate Affairs, Medtronic Korea, Co., Ltd., Seoul, South Korea
  • F5 : ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK

    Presentation

  • F5 : ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK

    Presentation

  • F6 : VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS EMERGING GOOD PRACTICES TASK FORCE: FINAL RECOMMENDATIONS

    Presentation

    Rachael Fleurence
    PhD, Program Director of Comparative Effectiveness Research Methods and Infrastructure Program, Patient Centered Outcomes Research Institute (PCORI), Washington, USA
    Anirban Basu
    PhD, Professor & Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, USA
    James F. Murray
    PhD, Research Fellow, Eli Lilly and Company, Global Health Outcomes - COE, Carmel, USA
    Lotte Steuten
    PhD, Member, Fred Hutchinson Cancer Research Center, Public Health Sciences, Seattle, USA
    Gillian D Sanders Schmidler
    PhD, Deputy Director, Academics and Professor of Population Health Sciences, School of Medicine, Duke University, The Robert J. Margolis, MD, Center for Health Policy, Washington, USA
  • F7 : ENABLING ISPOR MEMBER AND PATIENT ADVOCACY GROUP RESEARCH COLLABORATION: A VOLUNTEER PLAN

    Presentation

    Richard J. Willke
    PhD, Vice President, Outcomes & Evidence Lead CV/Metabolic, Pfizer Inc., Pain, Urology, Gender Health, Global Health & Value, New York, USA
    Laura T. Pizzi
    PharmD, MPH, Professor and Director, Rutgers University, Center for Health Outcomes Policy and Economics, Piscataway, USA
    Brian Ung
    PharmD, MS, Post-Doctoral Fellow, Celgene Corporation, US Health Economics and Outcomes Research, Summit, USA
    Jason Harris
    BA, Associate Director of Policy and Programs, National Health Council, Washington, USA
  • F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?

    Presentation

    Makoto Kobayashi
    PhD, M.Eng., Director and COO, CRECON Medical Assessment Inc., Tokyo, Japan
  • F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?

    Presentation

    Sukyeong Kim
    PHD, Director, National Evidence-Based Healthcare Collaborating Agency, Coordinating Center for National Health Clinical Research, Seoul, Korea, Republic of (South)
  • F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?

    Presentation

    Jitendar Sharma
    PhD, Head-Division of Healthcare Technology, Ministry of Health & Family Welfare, National Health Systems Resource Center, New Delhi, India
  • F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?

    Presentation

    Jianwei Xuan
    MD, PhD, Advisory Professor, Fudan University, School of Public Health, Shanghai, China
  • F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?

    Presentation

    Bor-Sheng Ko
    MD, PhD, Attending Physician and Clinical Assistant Professor, National Taiwan University Hospital, BMT Unit and Hematology Division, Department of Internal Medicine, Taipei, Taiwan
  • F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS

    Presentation

    Ramiro E. Gilardino
    MD, MSc, Director, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), Global Networks Latin America, Lawrenceville, USA
  • F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS

    Presentation

    Juan Carlos Alandete Manotas
    MD, MSc, MPH, MACS LATAM, Bayer, Whippany, USA
  • F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS

    Presentation

    Louis Garrison
    PhD, 2015-2016 ISPOR President-elect, Board of Directors and Professor, University of Washington, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, Seattle, USA
  • F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS

    Presentation

    Boxiong Tang
    MD, PhD, Partner, Perspective, Collegeville, USA